Chemotherapy and Immunotherapy of a Patient with Choriocarcinoma

Robinson, Emily; Ratzkowski, E

doi:10.1159/000303362

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to other gynecologic cancers, very few immunotherapeutic strategies have been studied for GTD so far. Before 1990, the few published papers were largely hypothetical as no convincing data were available to support the feasibility of immunotherapy (110)(111)(112)(113)(114)(115)(116) . During the 1990s, a single report was published suggesting that mouse trophoblasts could be used as immunogens for raising antibodies to human trophoblasts and that antibodies could distinguish normal trophoblasts from neoplastic trophoblasts.…”

Section: Hcgmentioning

confidence: 99%

Immunobiology of gestational trophoblastic diseases

Wang¹,

Fu²,

Freedman³

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

Gestational trophoblastic diseases (GTDs) comprise a group of interrelated diseases characterized by development after gestation, widespread metastases, and high curability with chemotherapy. The good prognosis of GTDs is considered partly a result of the host immune response to paternal antigens expressed on trophoblastic cells. In this study, we review current understanding of the immunobiology of GTDs. First of all, we describe the microenvironment between trophoblastic cells and subpopulation of immune cells. Second, immunogenetics, immune microenvironment around abnormal trophoblast, and mechanism of GTDs escaping from maternal immune system surveillance were also discussed. Third, we propose the possible immunotherapy for persistent GTDs, particularly the vaccine designed on human chorionic gonadotrophin, which is generally accepted as a tumor marker for GTDs diagnosis. Due to the low incidence of GTDs and high response to chemotherapy, there have been few literatures about immunobiologic characteristics of GTDs compared with the other gynecologic malignancies, such as ovarian cancer, but the immunologic behavior of GTDs should be explored for further understanding of the etiology of these diseases and to help designing immunotherapeutic strategies for persistent GTDs.

show abstract

Section: Hcgmentioning

confidence: 99%